Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery

Rectal Cancer Clinical Trial

— BACCHUS  

Official title:

A Phase II, Multicentre, Open-Label, Randomised Study of Neoadjuvant Chemotherapy and Bevacizumab in Patients With MRI Defined High-Risk Cancer of the Rectum

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01650428
• Other study ID #: UCL/09/0176
• Status: Completed
• Phase: Phase 2
• Start date: April 2013
• Est. completion date: February 14, 2019

Study information

• Verified date: October 2018
• Source: University College, London
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy, toxicity and feasibility of FOLFOX/ bevacizumab and FOLFOXIRI/ bevacizumab neoadjuvant therapy in poor prognosis rectal cancer as defined by MRI.

Description:

The purpose of this study is to look at two different combinations of anticancer drugs to see how effective they are at shrinking your cancer and preventing it from coming back after surgery. Patients with locally advanced rectal cancer are sometimes treated with radiotherapy, with or without chemotherapy, before having surgery. Radiotherapy treats only the main tumour in the rectum. This means that if tiny deposits of cancer have spread to other parts of the body (metastases), these could continue to grow. Giving chemotherapy and radiotherapy together (chemoradiotherapy) can treat both the main tumour and any spread. However, due to the side-effects we can't give as much chemotherapy in combination with radiotherapy than if chemotherapy were given on its own and treatment of possible metastases may not be as good as it could be. If the risk of the main tumour coming back is quite small, then giving treatment that targets metastases should be the best option.

This study looks at two well known combinations of chemotherapy drugs: FOLFOX (folinic acid, 5-fluorouracil, oxaliplatin) and FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, irinotecan). Chemotherapy works by killing cancer cells. In addition, the anticancer drug bevacizumab will be given with both the FOLFOX and FOLFOXIRI. Bevacizumab is an "anti-angiogenesis" drug. It works by stopping tumours from making new blood vessels. Without new blood vessels, the cancer cells do not get the food and oxygen they need to survive and grow. Attacking the cancer in these ways may be more effective than chemotherapy alone.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: February 14, 2019
• Est. primary completion date: January 10, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion

• Histologically confirmed diagnosis of adenocarcinoma of the rectum

• Distal part of the tumour within 4-12 cm of the anal verge

• No unequivocal evidence of established metastatic disease (on chest/abdominal/pelvis CT).Patients with equivocal lesions (as determined at MDT) are eligible

• MRI-evaluated locally advanced tumour with the following:

• T3 tumours extending (= 4 mm), beyond the muscularis propria N0-N2

• Or tumours (involving or threatening the peritoneal surface)

• OR presence of macroscopic extramural venous invasion (V2 disease)

• AND for tumours below the peritoneal reflection, the primary tumour or involved lymph node (on MRI) must be >1 mm from the mesorectal fascia

• Measurable disease (using RECIST criteria v1.1)

• WHO performance status 0 - 1

• In the opinion of the investigator:

• General condition considered suitable for radical pelvic surgery

• Candidate for systemic therapy with FOLFOX/FOLFOXIRI plus bevacizumab

• Adequate bone marrow, hepatic and renal function:

• Haemoglobin =80 g/L

• ANC =2 x 109/L

• Platelet count =100 x 109/L

• ALT or AST =1.5 x ULN (upper limit of normal)

• ALP =1.5 x ULN

• Total bilirubin =1.5 x ULN

• Serum creatinine =1.5 x ULN

• Creatinine clearance =50 mL/min using the Cockcroft-Gault formula

• INR = 1.1

• Urine protein =1+ with dipstick or urine analysis

• For proteinuria =2+ or urine protein/creatinine ratio = 1.0, 24-h urine protein should be obtained and the level must be =2 g for eligibility

• No evidence of established or acute ischaemic heart disease on ECG and normal clinical cardiovascular assessment

• No known significant impairment of intestinal absorption

• At least 18 years of age, but not more than 75 years

• Willing and able to give informed consent, comply with treatment and follow up schedule

Exclusion

• Disease outside of the mesorectal envelope (internal iliac/lateral pelvic lymph node)

• Clinically significant cardiovascular or coronary disease <2 years before randomisation

• History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan

• History of an arterial thromboembolic event during the previous 2 years

• Evidence of bleeding problems or coagulopathy

• Significant and continuing rectal bleeding leading to a haemoglobin <8 g/dL

• Patients receiving warfarin/coumarin derived anticoagulants at full therapeutic doses are excluded, but prophylactic doses of 1mg to prevent Hickman line clotting are eligible

• Chronic use of aspirin (>325 mg/day) or clopidogrel (>75 mg/day) within 10 days of first planned study treatment

• Require regular use of anti-diarrhoeal (e.g. daily use of loperamide)

• Serious uncontrolled intercurrent illness including poorly controlled diabetes mellitus

• Known hypersensitivity to any of the study drugs

• Serious wound, ulcer or bone fracture

• Current or impending rectal obstruction

• Metallic colonic or rectal stent in situ

• Previous pelvic radiotherapy

• Previous intolerance to fluoropyrimidine chemotherapy

• Previous treatment with bisphosphonates

• Infectious illness requiring antibiotics within 1 week of randomisation

• Previous treatment with another investigational agent within 30 days prior to randomisation

• Patients with a history of previous malignancy in the past 5 years, excepting basocellular or squamous cell skin cancer, or properly treated cervicouterine cancer in situ

• Known HIV, HBV or HCV infection

• Current smoker, or clinically relevant history of drug or alcohol abuse

• Pregnant or lactating women or pre menopausal women not using adequate contraception. Men and women of child-bearing potential must use adequate contraception

• Patients with any other condition or concurrent medical or psychiatric disease who, in the opinion of the investigator, is not eligible to enter the study

• Inability or unwillingness to comply with the protocol

Related Conditions & MeSH terms

• Rectal Cancer
• Rectal Neoplasms

Intervention

Biological:
• Bevacizumab
5 mg/kg, IV (in the vein) over 30-90 minutes, on day 1 of each 2 weekly cycles. Number of cycles: 1-5 (bevacizumab should not be administered during cycle 6).

Drug:
• Irinotecan
165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6
• Oxaliplatin
165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6
• 5-Fluorouracil
3200 mg/m2 IV (intravenous), continuous infusion over 48 hours starting on day 1 of two weekly cycle. Number of cycles: 1-6

Locations

Country	Name	City	State
United Kingdom	Blackpool Victoria Hospital	Blackpool
United Kingdom	Beatson West of Scotland Cancer Centre	Glasgow
United Kingdom	Charing Cross Hospital	London
United Kingdom	Guy's and St Thomas' Hospital	London
United Kingdom	Hammersmith Hospital	London
United Kingdom	North MiddlesexHospital	London
United Kingdom	Royal Marsden Hospitals NHS Foundation Trust	London
United Kingdom	UCLH	London
United Kingdom	Mount Vernon Hospital	Middlesex
United Kingdom	Wexham Park Hospital	Slough
United Kingdom	Lister Hospital	Stevenage

Sponsors (3)

Lead Sponsor	Collaborator
University College, London	Cancer Research UK, Hoffmann-La Roche

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pathological Complete Response (PCR)	The proportion of patients in each arm who achieve a pCR will be presented, along with a 95% CI. Within each group the achieved pCR rate will be compared to the rate achieved by radiotherapy alone (5%).	The pCR rate will be assessed after surgery, therefore approximately 24 weeks after randomisation.
Secondary	RECIST Response Rate	Complete response and Partial response will be considered as responses.	This will be assessed after chemotherapy has ended. Chemotherapy will be given for up to 12 weeks.
Secondary	CRM Negative Resection Rate	Those with a resection distance >1mm amongst those having surgery.	This will be assessed after surgery, therefore approximately 24 weeks after randomisation.
Secondary	T and N stage downstaging	This will examine T and N stage to assess whether stage has worsened from baseline to post-treatment. A patient will be considered to have downstaged if i) both T and N stage decrease; ii) either T or N stage decreases and the other remains stable.	This will be assessed at the completion of treatment. Treatment will be given for up to 12 weeks.
Secondary	Progression Free Survival	This is defined as time from randomisation to disease progression or death, whichever occurs first. Disease progression will be assessed by the RECIST criteria at pre-cycle 4 and post-treatment.	This will be assessed pre-cycle 4 and post-treatment, therefore at 6 weeks and 12 weeks after randomisation.
Secondary	Disease Free Survival	This is defined as the time from surgery with complete resections (R0) to the occurrence of relapse, second colorectal primary or death from any cause, whichever occurs first. Only subjects who have a complete resection (R0) will be included in this analysis. Patients who are alive, without recurrence and with no secondary colorectal cancer at the time of cut-off will be right-censored at the most recent date of assessment.	This will be length of time from date of surgery till relapse, second colorectal primary or death from any cause, whichever occurs first. These occurrences will be reported on CRFs every six months for up to three years.
Secondary	Overall Survival	This is defined as the time from study entry until death. The OS of all subjects and of the subgroup who had complete resection (R0) will be calculated.	From study entry until death, until 3 years after randomisation.
Secondary	Local Control	This will be assessed just for those patients who attain a CRM negative resection.	From date of surgery until local failure, until 3 years after randomisation.
Secondary	1 year Colostomy Rate	This will be assessed post-surgery. The Kaplan-Meier estimate will be used to estimate the colostomy rate at 1 year.	Post surgery (approximately 24 weeks after randomisation) and 1 year after randomisation.
Secondary	Frequency and severity of Adverse Events	This will be tabulated for both treatment arms, including all grade 1-5 toxicities.	This will be from date of randomisation until 30 days after completion of treatment. Treatment is given for up to 12 weeks.
Secondary	Compliance of Chemotherapy	Dose reductions and dose delays to all chemotherapy agents will be recorded.	This will be at the end of treatment (up to 12 weeks)
Secondary	Tumour Regression Grade (TRG)	This results from post-resection tumour sample will be used to categorise TRG into five groups using Dworak method.	Assessed after surgery, approximately 24 weeks after randomisation.
Secondary	Tumour Cell Density	This results from post-resection tumour sample will be used to provide an estimate of the average TCD and its 95% CI. This may be expressed as a mean, or if the date is skewed, the median.	This will be assessed after surgery, approximately 24 weeks after randomisation.